「Leishmaniasis」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
41行目: | 41行目: | ||
*same as Kala-azar | *same as Kala-azar | ||
**Latin "black fever" | **Latin "black fever" | ||
− | *fever | + | *incubation 3 weeks to >years |
− | *weight loss | + | *symptoms |
− | *hepatosplenomegaly | + | **fever -generally low grade |
− | *anemia | + | **weight loss |
+ | **hepatosplenomegaly - extremely substantial | ||
+ | ***completely subsides rapidly by treatment | ||
+ | **cough, diarrhea | ||
+ | **anemia, leukopenia, thrombocytopenia | ||
*many patients are asymptomatic and cured spontaneously | *many patients are asymptomatic and cured spontaneously | ||
**cell-mediated immunity | **cell-mediated immunity | ||
79行目: | 83行目: | ||
*importance of accurate diagnosis | *importance of accurate diagnosis | ||
**clinical features of VL resemble | **clinical features of VL resemble | ||
+ | *DDx | ||
+ | **chronic malaria | ||
+ | **schistosomiasis | ||
+ | **typhoid | ||
+ | **tuberculosis - splenomegaly is rare unless miliary TB | ||
+ | **hematological malignancy | ||
+ | *can be verically transmitted - rare | ||
+ | *Treatment | ||
+ | **to reduce parasite burden | ||
+ | **to improve complication | ||
+ | **to help to induce cell-mediated immunity | ||
+ | *Tx in India | ||
+ | **liposomal AMPH-B | ||
+ | ***+miltefosine | ||
+ | ***+paromomycin | ||
+ | ***+ | ||
+ | **AMPH-B - adherence is diffucult | ||
+ | **miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B | ||
+ | **drug interactions | ||
+ | *Tx in East Africa | ||
+ | ** | ||
+ | *Tx for ''L. infantum'' in Latin America | ||
+ | ** | ||
+ | |||
====post kala-azar dermal leishmanisis (PKDL)==== | ====post kala-azar dermal leishmanisis (PKDL)==== |
2021年4月26日 (月) 15:50時点における版
目次
taxonomy
- phylum Sarcomastigophorea, class Zoomastigophorea, genus Leishmania
- Plasmodium belongs to phylum Apicomplexa
morphology
- single flagellum
- kinetoplast - aggregation of DNA
- similar to Trypanosoma
epidemiology
- 700,000 - 1 mil. new cases per year
20,000-30,000 deaths per year
life cycle
- parasitize in human macrophage
- promastigote - 10-25 μm
- with flagellum
- transform from amastigote inside sandfly midgut
- proliferate inside midgut
- introduced into human skin directly from sandfly midgut during sandfly bite
- phagocytized by macrophage
- amastigote - 2-4 μm
- transform from promastigote and propagate inside macrophage
- transform to promastigote inside sandfly midgut
- simpler than Trypanosoma
- vector: sandfly
- host: human, dog, rodent
sand flly
- Phlebotomus spp.
- Eurasian
- Lutzomya spp.
- Latin America
- Feed during night
clinical manifestation
visceral leishmania
- most serious
- same as Kala-azar
- Latin "black fever"
- incubation 3 weeks to >years
- symptoms
- fever -generally low grade
- weight loss
- hepatosplenomegaly - extremely substantial
- completely subsides rapidly by treatment
- cough, diarrhea
- anemia, leukopenia, thrombocytopenia
- many patients are asymptomatic and cured spontaneously
- cell-mediated immunity
- 50,000-90,000 new cases reported per year 2004-2008
- 202,200-389,100 new cases estimated per year 2004-2008 - underreporting
- mainly children affected
- India, Ethiopia, South Sudan, Uganda, Brazil
- South Asia- decreasing trend towards elimination
- South Asia- epidemic wave pattern every 15 years
- East Africa- no decreasing trends
- East Africa-
- Latin America-
- L. donovani
- India, Africa
- anthroponotic = maintained in human-to-human infection
- L. infantum (formerly L. chagasi was thought separated species)
- Mediterranean, China, South America
- dog, cattle is reservoir
diagnosis of visceral leishmania
- suspect for >2 weeks fever+splenomegaly with geographical relation
- detection of amastigote in smear of bone marrow aspiration, lymph node or spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- 0.1% of life-threatening hemorrhage by spleen aspiration
- sensitivity 93-99% in spleen aspirate, 53-86% in bone marrow aspirate, 53-65% in lymph node aspirate
- culture in NNN media
- immunochromatographical detection of rk39 antigen
- dip stick form
- 97-100% sensitivity in Asia, low in Africa
- reason unkown, possibly the difference of subspecies
- cannot distinguish between active or relapse
- unkown sensitivity in HIV co-infection
- in areas of high HIV prevelence all leischmeniasis patients should be screened for HIV
- PCR
- importance of accurate diagnosis
- clinical features of VL resemble
- DDx
- chronic malaria
- schistosomiasis
- typhoid
- tuberculosis - splenomegaly is rare unless miliary TB
- hematological malignancy
- can be verically transmitted - rare
- Treatment
- to reduce parasite burden
- to improve complication
- to help to induce cell-mediated immunity
- Tx in India
- liposomal AMPH-B
- +miltefosine
- +paromomycin
- +
- AMPH-B - adherence is diffucult
- miltefosine - adherence is diffucult; now is only for combination with liposomal AMPH-B
- drug interactions
- liposomal AMPH-B
- Tx in East Africa
- Tx for L. infantum in Latin America
post kala-azar dermal leishmanisis (PKDL)
- skin manifestation after completion of Tx of visceral leishmaniasis
- macular type, papular type, nodular type
- Leishmania may be detected from skin specimen in some cases
- possible reservoir
cutaneous leishmania
- most common
- same as Oriental sore, Chiclero ulcer (in Latin America)
- papule, nodule → ulcer → scar
- basically self-limited
- rarely diffuce or disseminated
- 600,000-1 mil. new cases per year
- Afghanistan, Algeria, Brazil, Colombia, Iran, Syria
- imported in Texas, US in 2015
- L. tropica, L. mexicana, L. amazonensis and other species >20
- Rhombomys opimus (great gerbil) is primary reservoir
- cutaneous leishmaniasis by L. donovani is reported in Sri Lanka
diagnosis of cutaneous leishmaniasis
- smear of fine needle aspirate or biopsy of skin lesion
- serological test is of no use; low sensitivity and variable specificity
mucocutaneous leishmania
- same as Espundia, white leprosy
- lyphatic or hematogenous dissemination to mucosa in mouth and/or upper respiratory tract, resulted in destruction and deformity of nose, palate, pharynx
- L. braziliensis, L. panamensis
- Bolivia, Brazil, Peru
- progressive ever without treatment
- secondary bacterial infection
diagnosis of mucocutaneous leishmaniasis
- leishmania is scarce in mucosal lesion
- strong local immune response
- serology or molecular
emerging novel leishmaniasis
- in Thailand
- L. siamensis, L. martiniquensis
treatment
- pentavalent antimonial
- meglumine antimoniate
- sodium stibogluconate
- amphotericin B
- liposomal amphotericin B
- paromomycin
- pentamidine
- miltefosine
- cryotherapy
- liquid nitrogen
- thermotherapy
- 50℃ for 30min.
vaccine
- no human vaccine
- canine vaccine has been rolled out
- "leishmanization" in Uzbeskistan
- intradermal inoculation of live wild strain of L. major
control
- case detection and treatment for anthroponotic leishmaniasis
- vector control for sandfly-borne leishmaniasis
- destruction of burrows of great gerbil